Premium
Gene structure and expression analysis of the epidermal growth factor receptor, transforming growth factor‐alpha, myc, jun , and metallothionein in human ovarian carcinomas classification of malignant phenotypes
Author(s) -
Bauknecht Thomas,
Angel Peter,
Kohler Manuela,
Kommoss Friedrich,
Birmelin Gerlinde,
Pfleiderer Albrecht,
Wagner Edgar
Publication year - 1993
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19930115)71:2<419::aid-cncr2820710224>3.0.co;2-6
Subject(s) - ovarian cancer , biology , cancer research , epidermal growth factor , epidermal growth factor receptor , messenger rna , gene , northern blot , gene expression , transforming growth factor , tgf alpha , microbiology and biotechnology , cancer , receptor , endocrinology , genetics
This study reports the structure and expression rates of genes of the transforming growth factor‐alpha (TGF‐α) signal transduction pathway (TGF‐α, epidermal growth factor receptor [EGF‐R], jun, myc , and metallothionein [MT]) in 47 specimens of ovarian cancer and 21 nonmalignant tissues. The objective was to establish a direct correlation between the genetic activities and the malignant phenotype of the ovarian cancer. The Southern blot technique identified four samples with myc amplification and two with rearranged EGF‐R genes. By using the S1 nuclease assay, the analysis of myc transcription showed a similar use of both promotors. Although the size of the investigated transcripts was unaltered, significant differences in the transcription rates were noticed in malignant tissue probes (using northern blot analysis and RNAase protection assay). The following results of messenger RNA analysis in ovarian cancer were observed: EGF‐R, negative in 25%, low in 65%, and strongly positive in 10%; TGF‐α, negative in 34%, low in 36%, and strongly positive in 30%; myc , negative in 8%, low in 64%, and strongly positive in 28%; jun , negative in 4%, low in 58%, and strong in 38%; and MT, low in 80% and strongly positive in 20%. In most nonmalignant tissues studied, no or only a low expression of TGF‐α, EGF‐R, and myc . was found. A comparison of these messenger RNA results with the clinical data from tumors showed four different subgroups of ovarian carcinomas. The results of chemotherapy were known in 32 cases. Tumors with negative or low expression rates of all investigated genes did not respond to chemotherapy; 13 of 18 tumors with high expression rates did respond. Additional signal transduction chains distinct from the TGF‐α pathway, however, are likely to influence both the expression and activity of transcription factors and MT.